Januvia Gains Another Boost With FDA Warnings for Onglyza, Nesina
Executive Summary
Heart failure worries could limit use of AstraZeneca and Takeda products, and their relabeling can only help Merck's market leader.
You may also be interested in...
With VERTIS SITA2 On Board, Merck Eyes Broad Initial Approval For Ertugliflozin
In an interview at the European Association for the Study of Diabetes meeting, Merck exec Sam Engel explains the rationale behind the clinical trial strategy for the SGLT-2 inhibitor ertugliflozin, as it gears up with partner Pfizer for filings by the end of this year.
Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo
Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.